Literature DB >> 10911935

Ibogaine in acute opioid withdrawal. An open label case series.

K R Alper1, H S Lotsof, G M Frenken, D J Luciano, J Bastiaans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10911935     DOI： 10.1111/j.1749-6632.2000.tb06687.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  4 in total

1.  In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis.

Authors:  Jan Carlo Delorenzi; Leonardo Freire-de-Lima; Cerli R Gattass; Deise de Andrade Costa; Liwen He; Martin E Kuehne; Elvira M B Saraiva
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

2.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

3.  A meta-analysis of Chinese herbal medicine in treatment of managed withdrawal from heroin.

Authors:  Ting-ting Liu; Jie Shi; David H Epstein; Yan-Ping Bao; Lin Lu
Journal:  Cell Mol Neurobiol       Date:  2008-06-27       Impact factor: 5.046

4.  Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.

Authors:  Thomas Knuijver; Arnt Schellekens; Maarten Belgers; Rogier Donders; Toon van Oosteren; Kees Kramers; Robbert Verkes
Journal:  Addiction       Date:  2021-08-09       Impact factor: 7.256
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.